Amélie Provencher

Amélie Provencher

Auto-generated profile, based on publicly available information

Amélie Provencher

Neurosciences Axis Centre de recherche du CHU de Québec Université Laval Quebec City Quebec Canada

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CDCaroline Dallaire‐Théroux
Caroline Dallaire‐Théroux
HDHelena L. Denis
Helena L. Denis
RCRosalie Cottez
Rosalie Cottez
CTCyntia Tremblay
Cyntia Tremblay
APAmélie Provencher
Amélie Provencher
FCFrederic Calon
Frederic Calon
INTRODUCTION: Metabolic disorders are risk factors for Alzheimer's disease (AD), although underlying mechanisms remain unclear. We investigated the relationship between peripheral metabolic markers – adiponectin, fibroblast growth factor 21 (FGF‐21), and insulin‐like growth factor binding protein 2 (IGFBP‐2) – and AD. METHODS: Participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD, and cognitively healthy (CH) controls were from the Consortium for the Early Identification of Alzheimer's Disease–Quebec cohort ( n = 287). Serum adiponectin, FGF‐21, and IGFBP‐2 concentrations were measured, compared between groups, and assessed for associations with clinical, cognitive, biochemical, and magnetic resonance imaging (MRI) data. RESULTS: Metabolic dysfunction was linked to lower adiponectin and IGFBP‐2, but higher FGF‐21. Both FGF‐21 and IGFBP‐2 increased with age and were inversely associated with cognitive performance. IGFBP‐2 was elevated at SCD stage and correlated with plasma tau phosphorylated at threonine 181 and amygdala atrophy. Adiponectin was unrelated to cognition. DISCUSSION: These findings suggest that IGFBP‐2 and, to a lesser extent, FGF‐21 may serve as early biomarkers of cognitive impairment, reflecting intricate links between peripheral dysmetabolism and AD.